Innocare Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
1,259
- Stock Symbol
-
09969
- Investments
-
1
- Share Price
-
$1.48
- (As of Friday Closing)
Innocare General Information
Description
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Contact Information
Website
www.innocarepharma.comCorporate Office
- Building Number 8, Number 8 Life Science Park Road
- ZGC Life Science Park, Changping District
- Beijing, 102206
- China
Corporate Office
- Building Number 8, Number 8 Life Science Park Road
- ZGC Life Science Park, Changping District
- Beijing, 102206
- China
Innocare Stock Performance
As of 13-Nov-2026, Innocare’s stock price is $1.48. Its current market cap is $3.23B with 1.77B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.48 | $1.52 | $1.23 - $2.07 | $3.23B | 1.77B | 7.69M | $0.08 |
Innocare Financials Summary
As of 30-Jun-2026, Innocare has a trailing 12-month revenue of $397M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,542,489 | 2,298,485 | 778,753 | 627,389 |
| Revenue | 397,368 | 330,246 | 140,681 | 104,389 |
| EBITDA | 143,346 | 98,529 | (67,471) | (100,192) |
| Net Income | 131,323 | 89,339 | (61,408) | (89,226) |
| Total Assets | 1,651,076 | 1,546,958 | 1,288,680 | 1,399,307 |
| Total Debt | 279,817 | 184,247 | 174,182 | 190,349 |
Innocare Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Innocare Comparisons
Industry
Financing
Details
Innocare Competitors (30)
One of Innocare’s 30 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| RemeGen | Formerly VC-backed | Yantai, China | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA |
Innocare Patents
Innocare Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025218606-A1 | Antibody fusion protein as well as preparation therefor and use thereof | Pending | 16-Apr-2024 | ||
| US-11578058-B2 | Heterocyclic compounds for inhibiting tyk2 activities | Active | 11-Mar-2020 |
Innocare Signals
Innocare Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Innocare Investments (1)
Innocare’s most recent deal was a Joint Venture with Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences). The deal was made on 17-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences) | 17-Sep-2021 | Joint Venture | Drug Discovery |
Innocare ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
32.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Innocare FAQs
-
When was Innocare founded?
Innocare was founded in 2013.
-
Where is Innocare headquartered?
Innocare is headquartered in Beijing, China.
-
What is the size of Innocare?
Innocare has 1,259 total employees.
-
What industry is Innocare in?
Innocare’s primary industry is Drug Discovery.
-
Is Innocare a private or public company?
Innocare is a Public company.
-
What is Innocare’s stock symbol?
The ticker symbol for Innocare is 09969.
-
What is the current stock price of Innocare?
As of 13-Nov-2026 the stock price of Innocare is $1.48.
-
What is the current market cap of Innocare?
The current market capitalization of Innocare is $3.23B.
-
What is Innocare’s current revenue?
The trailing twelve month revenue for Innocare is $397M.
-
Who are Innocare’s competitors?
Alphamab Oncology, Inhibrx, Inovio Pharmaceuticals, RemeGen, and Sutro Biopharma are some of the 30 competitors of Innocare.
-
What is Innocare’s annual earnings per share (EPS)?
Innocare’s EPS for 12 months was $0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process